Sugi Predict

Sugi Predict / Compounds / SCHEMBL10051737

SCHEMBL10051737

SCHEMBL10051737

CC(C)[C@H]1OC[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.38

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ TYR P14679 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11954391 1.00 THRB (0.38) THRBLMNATYR
SCHEMBL9914081 1.00 THRB (0.38) THRBLMNATYR
SCHEMBL16491129 1.00 THRB (0.38) THRBLMNATYR
SCHEMBL11946930 1.00 THRB (0.38) THRBLMNATYR
SCHEMBL14025402 1.00 THRB (0.38) THRBLMNATYR
SCHEMBL24988552 1.00 THRB (0.38) THRBLMNATYR
SCHEMBL12311766 1.00 THRB (0.38) THRBLMNATYR
SCHEMBL14556001 1.00 THRB (0.38) THRBLMNATYR
SCHEMBL12311769 1.00 THRB (0.38) THRBLMNATYR
SCHEMBL11083921 1.00 THRB (0.38) THRBLMNATYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013096697-A2 ISOLATION, IDENTIFICATION, AND USED OF ANTIFUNGAL COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2013-06-27 — — WO disclosed
US-20130156788-A1 FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 OXFORD BIOTHERAPEUTICS LTD (GB) 2013-06-20 — — US disclosed
US-8420084-B2 Fully human antibodies specific to CADM1 MEDAREX, INC. (US) 2013-04-16 — — US disclosed
US-20120093826-A1 FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 OXFORD BIOTHERAPEUTICS LTD (GB) 2012-04-19 — — US disclosed
US-20120027782-A1 MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-02 — — US disclosed
US-20110085970-A1 ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE BRISTOL-MYERS SQUIBB COMPANY 2011-04-14 — — US disclosed
US-20110020329-A1 CONJUGATES OF ANTI-RG-1 ANTIBODIES BRISTOL-MYERS SQUIBB COMPANY 2011-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110085970-A1 ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE CD2BP2, CD274, CD22 THRB 3934/4885LMNA 4374/4885TYR 4436/4885
US-20120093826-A1 FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 FCGR1A, FCGR2A, FCGR3B THRB 2746/4885LMNA 3493/4885TYR 4753/4885
US-20130156788-A1 FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 FCGR1A, FCGR2A, FCGR3B THRB 2746/4885LMNA 3493/4885TYR 4753/4885
US-20110020329-A1 CONJUGATES OF ANTI-RG-1 ANTIBODIES GDI1, ARFGAP1, GLG1 THRB 3315/4885LMNA 3892/4885TYR 4786/4885
US-20120027782-A1 MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) PTK2, PTK2B, LTK THRB 3260/4885LMNA 4502/4885TYR 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.